USpolicy

News

FDA ramps up its pushback against compounded GLP-1s

In a move that will please Novo Nordisk and Eli Lilly, the FDA sent warnings to 30 telehealth firms, accusing them of illegally marketing GLP-1 drugs.

News

CMS extends deadline for MFN pricing pilot scheme

CMS has extended the deadline for its Medicaid drug pricing pilot, GENEROUS, to "provide interested drug manufacturers more opportunity to join."

News

US lawmakers take FDA to task over rare diseases record

Lawmakers and patient advocates in the US are concerned that the FDA's regulation of rare disease therapies has been inconsistent and overly cautious.

News

In brief SOTU remarks, Trump asks Congress to "codify" MFN

In a speech at least nominally focused on the economy and affordability, President Trump put surprisingly little emphasis on his drug pricing efforts.

News

FDA maps new regulatory route for ultra-rare diseases

The FDA has sketched out its 'plausible mechanism' regulatory pathway for individualised therapies that treat ultra-rare diseases.

News

Scrabble lettering of Two and One on grass

Makary says FDA will "end two-trial dogma" for approvals

The FDA plans to adopt a new policy that will do away with the default requirement to base regulatory filings for new medicines on two pivotal trials.

FDA ramps up its pushback against compounded GLP-1s

CMS extends deadline for MFN pricing pilot scheme

US lawmakers take FDA to task over rare diseases record

In brief SOTU remarks, Trump asks Congress to "codify" MFN

FDA maps new regulatory route for ultra-rare diseases

Makary says FDA will "end two-trial dogma" for approvals

Doctors dismayed by report of NHS AI proposal

Discover a new era of healthcare panel engagement: Grounded ...

USpolicy

Editor's Picks